Obsidian Therapeutics is a clinical-stage biopharmaceutical company focused on developing amsoki-cel (formerly OBX-115). As of November 9, 2026, the company had 61,774,046 shares of common stock outstanding and continues to incur significant financial losses to fund its research and development programs.
Obsidian Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $324.4 million following its Nasdaq debut and a $350 million financing. The company is advancing its lead TIL cell therapy candidate, amsoki-cel, with enrollment in a registration-enabling melanoma cohort expected to complete in Q1 2027.
Term
3 years
“2026 has been a transformative year so far for Obsidian. In the third quarter, we closed an oversubscribed $350 million financing, completed our transaction with Galera Therapeutics, and debuted on Nasdaq as a publicly traded company.”
Madan Jagasia, M.D., Chief Executive Officer
“The updated data we presented at SITC further strengthen our belief in the program, highlighting amsoki-cel’s consistent, favorable safety profile and encouraging clinical activity in patients with advanced melanoma, including an objective response rate of 67%, median progression-free survival of 8.3 months, and median duration of response not yet reached at median study follow-up of 14.3 months.”